Oxford Biomedica Regulatory News (OXB)

16 May 2005 07:01

Oxford Biomedica PLC16 May 2005 FOR IMMEDIATE RELEASE 16 MAY 2005 OXFORD BIOMEDICA PRESENTS UPDATED AND ENCOURAGING TROVAX(R) PHASE II RESULTS IN COLORECTAL CANCER AT THE 2005 ANNUAL MEETING Oxford, UK: 16 May 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapycompany, today announced that new and encouraging data were presented from thePhase II trials of TroVax, its cancer immunotherapy, in colorectal cancer at the2005 American Society of Clinical Oncology (ASCO) Annual Meeting, in Orlando,Florida, USA, on Sunday, 15 May 2005. The presentation included data reported in March 2005 from the two Phase IItrials in first line treatment of metastatic colorectal cancer alongsideirinotecan-based (IFL) and oxaliplatin-based (FOLFOX) chemotherapy. In addition,further immune response data were presented. These show that the maximumantibody levels (titres) targeted against the 5T4 tumour antigen in the Phase IIstudies are significantly higher than in the Phase I/II trial inpost-chemotherapy patients. Peak titres reached levels of 5,000 in theTroVax+IFL trial and 1,200 in the TroVax+FOLFOX trial. These are four- toten-fold higher than in the Phase I/II study. This may be important because, inthat earlier study, there was a highly significant (p